CD47 and neoplasm: Studies have demonstrated that by delivering TLR7/8 agonists (R848) (111) or targeting CD47 (184) and Siglec-G (185) with siRNA, ultrasound-responsive nanoplatforms can effectively reprogram pro-tumor M2 macrophages into anti-tumor M1 phenotypes.